Immuneering Corp (IMRX) SEC Filings, Mar-Jun 2026

Immuneering Corp director Laurie Keating received a grant of 33,350 stock options. These options allow her to buy Class A common stock at an exercise price of $4.12 per share and are held directly.

The options vest in equal monthly installments over one year starting on July 11, 2026. They will be fully vested and exercisable on June 11, 2027, or on the date of the 2027 annual meeting of stockholders, whichever occurs first. After this grant, Keating holds 33,350 stock options in total.

Immuneering Corp director Peter Feinberg received a grant of stock options covering 33,350 shares of Class A common stock. The options have an exercise price of $4.12 per share and expire on June 11, 2036. They vest in equal monthly installments over one year starting July 11, 2026, becoming fully vested by June 11, 2027 or the 2027 annual stockholder meeting, whichever comes first. Following this grant, Feinberg holds 33,350 stock options directly.

Immuneering Corporation held its Annual Meeting of Stockholders on June 11, 2026, where stockholders voted on director elections and the auditor appointment. A total of 44,495,059 Class A common shares were present in person or by proxy, representing approximately 68.8 percent of shares outstanding as of the April 15, 2026 record date.

Stockholders elected Peter Feinberg and Laurie B. Keating as Class II directors to serve until the 2029 Annual Meeting, with 26,420,287 and 27,121,501 votes for their election, respectively, and no votes against. Stockholders also approved the ratification of RSM US LLP as the independent registered public accounting firm for the year ending December 31, 2026, with 42,142,848 votes for and 1,920,218 against.

Immuneering Corporation reported updated Phase 2a results for its oral MEK inhibitor atebimetinib plus modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer. As of the April 24, 2026 cutoff, median overall survival in the 320 mg intent-to-treat group of 55 patients was 17.3 months, compared with an 8.5‑month median overall survival reported for the standard of care from the MPACT trial.

Median progression-free survival in this group was 8.3 months. Among 50 response‑evaluable patients, overall response rate was 36% and disease control rate was 82%. In patients with sufficient data, 84% maintained or gained weight relative to baseline.

The combination was generally well tolerated, with Grade ≥3 anemia in 16% of patients and neutropenia in 18%, and no Grade 5 treatment‑emergent adverse events. Immuneering outlined plans to start a pivotal Phase 3 MAPKeeper 301 trial in mid‑2026 with topline data expected in mid‑2028, along with additional lung cancer and preclinical programs through 2027.

Immuneering Corporation is a late-stage clinical oncology company developing Deep Cyclic Inhibitors targeting the MAPK pathway, led by atebimetinib (IMM-1-104). The drug is moving into MAPKeeper 301, a global Phase 3 registrational trial in first-line metastatic pancreatic cancer, planned to enroll about 510 patients.

For the three months ended March 31, 2026, Immuneering reported a net loss of $13,460,895, modestly improved from $15,046,132 a year earlier, with basic and diluted net loss per share of $0.21 versus $0.42. Operating expenses were $15,335,034, driven mainly by $10,645,222 in research and development and $4,682,495 in general and administrative costs.

Cash and cash equivalents were $47,321,566 and marketable securities totaled $151,322,802 as of March 31, 2026, supporting management’s view that current resources can fund operations into 2029. The company remains pre-revenue, focused on advancing atebimetinib through late-stage trials and progressing its broader oncology pipeline, including envometinib (IMM-6-415).

Immuneering Corporation reported first-quarter 2026 results and highlighted progress in its oncology pipeline. The company ended March 31, 2026 with $198.6 million in cash, cash equivalents and marketable securities and expects this to fund operations into 2029.

R&D expenses were $10.6 million and G&A expenses were $4.7 million. Net loss attributable to common stockholders was $13.5 million, or $0.21 per share, compared with $15.0 million, or $0.42 per share, a year earlier.

Clinically, new survival data from 55 first-line pancreatic cancer patients treated with atebimetinib plus mGnP will be presented in an oral session at the 2026 ASCO Annual Meeting. The pivotal Phase 3 MAPKeeper 301 trial in first-line metastatic pancreatic cancer is now recruiting, and a Phase 2 lung cancer trial is planned to start dosing in the second half of 2026. The company also reported a third-line pancreatic cancer patient on atebimetinib monotherapy with 27 months progression-free survival and an ongoing 85% tumor burden reduction.

Immuneering Corporation is holding a virtual 2026 annual stockholder meeting on June 11, 2026 at 11:00 a.m. Eastern Time. Stockholders will vote on electing two Class II directors, Peter Feinberg and Laurie B. Keating, to terms running to the 2029 annual meeting, and on ratifying RSM US LLP as independent registered public accounting firm for the year ending December 31, 2026. Holders of 64,697,227 outstanding shares of Class A common stock as of April 15, 2026 are entitled to one vote per share and may vote by internet, telephone, mail, or during the live webcast.

Immuneering Corp’s Chief People Officer, Leah R. Neufeld, acquired additional company stock through an employee plan. She obtained 3,628 shares of Class A Common Stock on the ESPP Purchase Date of March 13, 2026 at $4.2925 per share, under the 2021 Employee Stock Purchase Plan for the offering period from September 16, 2025 through March 15, 2026. The plan price was set at not less than 85% of the fair market value on the purchase date. Following this routine, compensation-related acquisition, Neufeld directly holds 29,598 shares, and the transaction is exempt under Rule 16b-3(c).

Immuneering Corporation is a late-stage clinical oncology company developing Deep Cyclic Inhibitors, a new class of targeted cancer drugs designed to intermittently block tumor signaling while sparing healthy cells.

Lead candidate atebimetinib (IMM-1-104), an oral MEK inhibitor, is moving toward a global Phase 3 MAPKeeper 301 trial in first-line metastatic pancreatic ductal adenocarcinoma, with about 510 patients planned and first dosing expected in mid-2026. Positive Phase 1/2a data in pancreatic cancer showed encouraging survival and tolerability, and the drug holds FDA Fast Track and orphan designations for pancreatic cancer and Fast Track for NRAS-mutant melanoma.

Second program envometinib (IMM-6-415) showed promising early PK/PD and safety but has been paused internally while partnership options are explored.

For 2025, Immuneering reported a net loss of $56.0M on operating expenses of $59.4M, mainly R&D. Significant 2025 equity offerings lifted cash, cash equivalents and marketable securities to $217.0M, which management believes can fund operations into 2029.